Charles Magness, PhD
President, Chief Executive Officer, Director
Dr. Charles Magness co-founded Kineta in December 2007 and is responsible for determining and achieving corporate goals including corporate strategy, execution of all corporate initiatives, corporate development and capital funding. He also is focused on development of intellectual property and serving as interim Chief Financial Officer. Dr. Magness, along with Kineta co-founder Dr. Iadonato, previously founded venture-backed Illumigen Biosciences, Inc. of Seattle in 2000. As initially CIO and then President and COO from 2003-2007, Dr. Magness lead the company from inception to acquisition by Cubist Pharmaceuticals in 2007. During his tenure, Illumigen raised over $23 million through financing and business development activities, contractual revenue, and grants. At Illumigen, he also was responsible for investor relations, intellectual property and licensing, and computational analysis. In addition to creating Illumigen's patented biostatistical computing platform, Dr. Magness has more than 25 years experience developing and managing statistical solutions for large scientific projects, most notably the Human Genome Project. Prior to joining Illumigen, he was an NIH-funded researcher at the University of Washington (UW) where he managed sequence data analysis for the UW Genome Center and co-developed SEGMAP, a widely used and highly acclaimed tool essential for mapping the human genome. He is co-inventor on a US and an international patent. He also has more than 35 pending patent applications. Dr. Magness has previously held positions at Washington University in St. Louis, McDonnell Douglas Research Laboratories, and with the US Army. He received his Ph.D. from Lehigh University.

Shawn Iadonato, PhD
Executive Vice President, Chief Scientific Officer, Director
Dr. Shawn Iadonato co-founded Kineta in December of 2007. As Chief Scientific Officer his principal responsibility is determining Kineta's research and development priorities. Dr. Iadonato also heads up both the scientific advisory and evaluation teams responsible for identifying and evaluating in-licensing and other developmental opportunities. Previously, Dr. Iadonato co-founded and served as CSO of Illumigen Biosciences, Inc. There, he pioneered Illumigen's patented drug discovery methodology which relied upon recruitment and screening of healthy populations. He also led the successful discovery and preclinical development of Illumigen's anti-Hepatitis C drug which ultimately resulted in the successful sale of the company in December, 2007. Prior to founding Illumigen, Dr. Iadonato managed the Human Genome Project data collection effort at the University of Washington Genome Center. He has also been central in several other large scientific collaborations and has served on a number of National Institutes of Health scientific review panels. He is co-inventor on more than 35 patents or pending applications, has been principal investigator on US federally funded research programs, and is frequently an invited lecturer. He received a Ph.D. in Genetics from the University of Washington and his undergraduate degree from University of Pennsylvania. Dr. Iadonato is avid follower of national and regional affairs, and enjoys fishing and hunting. He is married and lives with his wife and their young daughter in Seattle.

William Cadwallader
Senior Vice President Corporate Development
Mr. Cadwallader joins Kineta to design and lead the company's corporate development strategies. He has over 24 years of experience in corporate development, marketing and strategic planning. Prior to joining Kineta, Mr. Cadwallader served as Executive Vice President of Corporate Development at Velcura Therapeutics where he drove a successful corporate strategy. Velcura is a clinical stage biotechnology company based in Ann Arbor, Michigan. Earlier, Mr. Cadwallader was Vice President for Strategic Planning and Marketing, at Cell Therapeutics, Inc., where his position was integral to the product license and alliance management of Cell Therapeutics' oncology product collaboration with pharmaceutical giant, Novartis. Mr. Cadwallader also held numerous positions at Amgen, Thousand Oaks, CA. There, he took on increased responsibilities following each advancement, holding key positions in strategic planning, marketing, global marketing and product licensing. In addition, he played an essential role in the launch of Neulasta® (pegfilgrastim); now a $3 billion franchise product. Mr. Cadwallader also was part of the successful joint venture of Sankyo and Parke Davis, helping to establish the U.S. commercial presence of Sankyo Ltd., Japan’s second largest pharmaceutical company. Mr. Cadwallader began his career as a sales representative for the Upjohn Co., Kalamazoo, Michigan. He enjoys running and spending time on his boat. He lives in Seattle with his wife Jenny and their two dogs, Leo and Ruby.

Kenneth North
Senior Vice President, Finance
Ken North is senior vice president of finance at Kineta. His primary responsibility is generating financing for Kineta and its array of drug development programs. Ken strategically matches Kineta's short and long term goals with those of investors. As a member of Kineta's executive team, Ken also contributes to high level financial and strategic planning. He also ensures that investors are given high quality and frequent updates on Kineta's scientific and business developments. Prior to joining Kineta in 2008, Ken spent nearly thirty years leading, and earlier managing several financial institutions. Most recently Ken served as President and CEO at Seattle Savings Bank. There, Ken was responsible for creating the successful business and marketing plans for the bank and greatly enhancing its value by developing unique product lines. Ken also was instrumental in launching and licensing Seattle Savings Bank at its inception. Before that, Ken held key leadership positions at Metropolitan Savings Bank and was responsible for managing $90 million in deposits. Ken gives back generously to many important community organizations holding leadership roles and serving on boards for Kiwanis Club of Seattle, Greater Seattle Chamber of Commerce, First Place and serving as Seattle Seafair Commandant, 2009.

P. Campion Fellin, MSE
Vice President, Operations
Mr. Fellin was instrumental in the seamless startup of Kineta and oversees Kineta operations including the direct oversight of Kineta bioinformatics programs. He has direct responsibility for managing implementation of business development activities and finance and budget corporate matters. Mr. Fellin comes to Kineta with more than 20 years business and management experience, including enterprise application development and project management. Mr Fellin also was part of the Illumigen team and he held positions of increasing responsibility, most recently as Director of Bioinformatics. He was responsible for all bioinformatics development and information technology systems which included development of biological analysis software supporting pre-clinical development activities. He also was responsible for managing all third-party commercial and academic bioinformatics relationships. Prior to Illumigen, he was a manager at 360 Powered Corporation, specializing in commercial software development. He also held previous positions with high technology companies, specializing in advanced software development, such as WRQ, Attachmate Corporation, and both the military and commercial divisions of The Boeing Company.